Last updated: 4 July 2020 at 1:03pm EST

Lucia Celona Net Worth



Lucia Celona APLS stock SEC Form 4 insiders trading

Lucia has made over 1 trades of the Apellis Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Lucia exercised 3,744 units of APLS stock worth $143,620 on 14 February 2018.

The largest trade Lucia's ever made was exercising 3,744 units of Apellis Pharmaceuticals Inc stock on 14 February 2018 worth over $143,620. On average, Lucia trades about 468 units every 0 days since 2017. As of 14 February 2018 Lucia still owns at least 22,780 units of Apellis Pharmaceuticals Inc stock.

You can see the complete history of Lucia Celona stock trades at the bottom of the page.



What's Lucia Celona's mailing address?

Lucia's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, WALTHAM, MA, 02451.

Insiders trading at Apellis Pharmaceuticals Inc

Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, ePascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.



What does Apellis Pharmaceuticals Inc do?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.



What does Apellis Pharmaceuticals Inc's logo look like?

Apellis Pharmaceuticals Inc logo

Apellis Pharmaceuticals Inc executives and stock owners

Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: